FSD Pharma logo

FSD PharmaNASDAQ: HUGE

Profile

Sector:

Healthcare

Country:

Canada

IPO:

08 June 2018

Next earnings report:

14 November 2024

Last dividends:

N/A

Next dividends:

N/A
$248.26 M
-95%vs. 3y high
56%vs. sector
-vs. 3y high
-vs. sector
-83%vs. 3y high
99%vs. sector
-vs. 3y high
-vs. sector

Price

regular market | Wed, 16 Oct 2024 13:30:00 GMT
$5.39(0.00%)

Dividend

No data over the past 3 years
$0.00$710.00 K
$0.00-$3.11 M

Analysts recommendations

Institutional Ownership

HUGE Latest News

FSD Pharma Selected to Present its Phase 1 Data on Lucid-MS at MSMilan 2023 – 9th Joint ECTRIMS-ACTRIMS Meeting for October 11-13, 2023
Accesswire15 August 2023 Sentiment: POSITIVE

Targeting the Approximate $22 Billion Multiple Sclerosis Drug Treatment Market TORONTO, ON / ACCESSWIRE / August 15, 2023 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders, is pleased to announce that its late breaking abstract about Phase 1 first-in-human data on Lucid-MS (Lucid-21-302) was selected for presentation at the upcoming MSMilan 2023 - 9th Joint ECTRIMS-ACTRIMS meeting scheduled for October 11-13, 2023. Lucid-MS is a potential drug candidate for multiple sclerosis (MS) targeting demyelination, the loss of the protective myelin sheath, in the central nervous system.

FSD Pharma to Present at Sidoti Virtual Investor Conference May 10-11
Business Wire08 May 2023 Sentiment: NEGATIVE

TORONTO--(BUSINESS WIRE)---- $HUGE #FSDPharma--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, today announced Mr. Zeeshan Saeed, President and Executive Co-Chairman, and Dr. Lakhsmi Kotra, Executive Director and CEO Lucid Psycheceuticals, will present and host one-on-one meetings wit.

What type of business is FSD Pharma?

FSD Pharma Inc., a biopharmaceutical company, researches and develops a portfolio of assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, and alcohol misuse disorders with drug candidates in different stages of development. The company operates through two segments, Biopharmaceutical and Strategic Investments. Its lead compound is Lucid-MS, a patented new chemical entity that is in Phase 2 clinical trial to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis, in preclinical models. The company is also developing a treatment for alcohol misuse for application in hospitals and other medical practices. In addition, it maintains a portfolio of strategic investments comprising loans secured by residential property. FSD Pharma Inc. is headquartered in Toronto, Canada.

What sector is FSD Pharma in?

FSD Pharma is in the Healthcare sector

What industry is FSD Pharma in?

FSD Pharma is in the Drug Manufacturers - Specialty & Generic industry

What country is FSD Pharma from?

FSD Pharma is headquartered in Canada

When did FSD Pharma go public?

FSD Pharma initial public offering (IPO) was on 08 June 2018

What is FSD Pharma website?

https://www.fsdpharma.com

Is FSD Pharma in the S&P 500?

No, FSD Pharma is not included in the S&P 500 index

Is FSD Pharma in the NASDAQ 100?

No, FSD Pharma is not included in the NASDAQ 100 index

Is FSD Pharma in the Dow Jones?

No, FSD Pharma is not included in the Dow Jones index

When was FSD Pharma the previous earnings report?

No data

When does FSD Pharma earnings report?

The next expected earnings date for FSD Pharma is 14 November 2024